AI summary · may contain errors
Across German online marketplaces (March 2025–May 2026), 282 commercial electric breast pump models from 108 brands ranged from 19.99 to 659.57 EUR, with a median of 72.70 EUR.
- Open access
Moving in medRxiv, Clinical Infectious Diseases, JAMA Internal Medicine, European Respiratory Journal, PLOS Medicine, Genetics in Medicine, JNCI: Journal of the National Cancer Institute and Journal of Clinical Oncology.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Across German online marketplaces (March 2025–May 2026), 282 commercial electric breast pump models from 108 brands ranged from 19.99 to 659.57 EUR, with a median of 72.70 EUR.
AI summary · may contain errors
A four-step FAIR-PROs pathway is proposed to make patient-reported outcomes reusable at scale by linking measurement, routine capture, standards, and analytic reuse across settings.
AI summary · may contain errors
MRS-based health checks for cardiometabolic risk in Finland’s 50–54-year-old working-age population reduce healthcare workload, saving 193,140 nurse hours and 2,843 physician hours over five years.
AI summary · may contain errors
Economic evaluation should be central to malaria decision making because it provides a transparent way to weigh health benefits against resources when allocating scarce funds across heterogeneous areas and populations.
AI summary · may contain errors
Global economic evaluation of COVID-19 vaccination from 8 December 2020 to 8 December 2021 estimates return-on-investment of $59.7–$809 per dollar invested in the base case.
AI summary · may contain errors
In 2023, working-age (15–64) musculoskeletal disorders produced 119.4 million DALYs globally, rising 77.2% since 1990, with 98.6% of DALYs nonfatal.
AI summary · may contain errors
Utility-weighted analysis of the modified Rankin Scale (mRS) is increasingly used in acute stroke trials to quantify patient-valued health states, not just rank order.
AI summary · may contain errors
Net annualized cancer-attributable medical service costs were highest in the end-of-life phase at $121,746, exceeding initial ($45,063) and continuing ($7,141) phases in SEER-Medicare older adults.
AI summary · may contain errors
Each 10-point increase in total ESAS symptom burden is linked to a 9.4% decrease in 30-day cancer-directed treatment costs in Ontario adults after diagnosis.
AI summary · may contain errors
Testing hepatitis C virus (HCV) more frequently in US men who have sex with men (MSM) is cost-effective, with an optimal strategy at an ICER of $67 092/QALY gained.
AI summary · may contain errors
Non-pharmacological, non-surgical guideline-recommended interventions for non-specific low back pain are often cost-effective versus usual care, with many potentially cost-saving at a £20,000 willingness-to-pay threshold.
AI summary · may contain errors
Across 56 studies (from 27,087 unique records) evaluating hereditary cancer testing, 76.6% of base-case analyses found GGT cost-effective or cost-saving despite major heterogeneity in strategies and comparators.
AI summary · may contain errors
An IRAOOPcap of $2,000 annual out-of-pocket costs for Medicare Part D beneficiaries with newly diagnosed multiple myeloma is projected to yield 0.17–0.18 life-years gained in ages 66–75 under realistic-to-best IMiD adherence scenarios.
AI summary · may contain errors
Population-weighted mean delivery costs per vaccine dose in 136 LMICs are $4.27 for routine childhood, $20.56 for adolescent, and $14.71 for campaign vaccination in 2024 US dollars.
AI summary · may contain errors
Adding patient-reported outcomes to machine learning models improves prediction of overall survival benefit in 100 FDA oncology drug approval trials, raising AUC-ROC from 0.67 to 0.79.
Journals this month
Topics moving, week to 17 Nov 2026
By field